cd19 car-t cytokine release syndrome
The $1.2B Chronic Disease Management Crash This Trial Avoided
79% of patients in the CASTLE trial developed cytokine release syndrome (CRS), but a pre-emptive monitoring protocol stopped the cascade of complications that would have cost billions. The trial shows that precise, timed intervention beats the reactive, costly models we use for severe autoimmune disease. Medical Disclaimer: This article is